Celcuity (NASDAQ:CELC) Hits New 1-Year High – Still a Buy?

Celcuity, Inc. (NASDAQ:CELC)’s share price hit a new 52-week high on Tuesday . The company traded as high as $129.09 and last traded at $125.68, with a volume of 995407 shares changing hands. The stock had previously closed at $121.03.

Analysts Set New Price Targets

A number of brokerages recently weighed in on CELC. Citizens Jmp assumed coverage on Celcuity in a report on Monday. They issued a “market outperform” rating and a $150.00 target price on the stock. Stifel Nicolaus raised their price objective on Celcuity from $115.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Wolfe Research reissued an “outperform” rating and issued a $110.00 price objective on shares of Celcuity in a research report on Thursday, March 12th. Wall Street Zen lowered Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $122.00 price objective on shares of Celcuity in a research report on Thursday, March 26th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $114.33.

Celcuity Stock Up 3.8%

The firm has a 50-day simple moving average of $113.72 and a 200 day simple moving average of $101.08. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55. The company has a market capitalization of $6.08 billion, a PE ratio of -33.16 and a beta of 0.41.

Celcuity (NASDAQ:CELC) last released its quarterly earnings data on Wednesday, March 25th. The company reported ($0.97) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.09. On average, research analysts predict that Celcuity, Inc. will post -3.97 EPS for the current fiscal year.

Insider Activity

In other news, Director Richard E. Buller sold 3,000 shares of Celcuity stock in a transaction dated Tuesday, March 31st. The stock was sold at an average price of $110.27, for a total transaction of $330,810.00. Following the sale, the director directly owned 6,760 shares of the company’s stock, valued at approximately $745,425.20. The trade was a 30.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 13.33% of the company’s stock.

Institutional Trading of Celcuity

A number of hedge funds and other institutional investors have recently modified their holdings of CELC. Avoro Capital Advisors LLC purchased a new stake in shares of Celcuity during the fourth quarter worth about $310,302,000. NEA Management Company LLC increased its position in shares of Celcuity by 64.9% during the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock worth $352,637,000 after acquiring an additional 1,391,300 shares during the last quarter. State Street Corp increased its position in shares of Celcuity by 126.6% during the fourth quarter. State Street Corp now owns 1,637,687 shares of the company’s stock worth $163,343,000 after acquiring an additional 914,887 shares during the last quarter. Apis Capital Advisors LLC purchased a new stake in shares of Celcuity during the third quarter worth about $38,334,000. Finally, UBS Group AG increased its position in shares of Celcuity by 910.1% during the third quarter. UBS Group AG now owns 854,483 shares of the company’s stock worth $42,211,000 after acquiring an additional 769,891 shares during the last quarter. 63.33% of the stock is owned by hedge funds and other institutional investors.

About Celcuity

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.